Amgen: all 1,085 studies

Page 10 of 11. Open to participants first (51), then studies with results posted, then the rest; newest registration first within each.

• Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin AlfaCompletedNCT00540696Phase 2
• A Phase II Study of CCX282-B in Patients With Celiac DiseaseCompletedNCT00540657Phase 2
• Dose-finding Study of Novel Erythropoiesis Stimulating Protein (NESP) for the Treatment of Anaemia in Subjects With Solid Tumours Receiving Multicycle ChemotherapyCompletedNCT00540384Phase 1/2
• The SPECTRA StudyTerminatedNCT00537667Phase 2
• An Exploratory Sub-study for the RED-HF™ (Reduction of Events With Darbepoetin Alfa in Heart Failure) TrialTerminatedNCT00534456Phase 3
• A Phase 1b/2 Study of AMG 655 in Combination With Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung CancerCompletedNCT00534027Phase 1/2
• Study to Assess Fixed Dosing of AMG 223 in Subjects With Chronic Kidney Disease on Hemodialysis With HyperphosphatemiaCompletedNCT00530114Phase 2
• Safety and Efficacy Study of AMG 073 in Hemodialysis SubjectsCompletedNCT00527267Phase 3
• Phase 2 Study of Darbepoetin Alfa Extended DosingCompletedNCT00527215Phase 2
• NESP Pediatric StudyCompletedNCT00527137Phase 3
• 12-month Study of AMG 073 in Renal OsteodystrophyCompletedNCT00527085Phase 2
• Fixed Dose NESP Study in Subjects With CRICompletedNCT00526929Phase 2
• Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer PatientsCompletedNCT00511459Phase 2
• A Study of AMG 951 [rhApo2L/TRAIL] in Subjects With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy +/- BevacizumabCompletedNCT00508625Phase 2
• Safety, Pharmacokinetic and Pharmacodynamic Study of MP-376 in Patients With Cystic FibrosisCompletedNCT00503490Phase 1
• Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal CancerCompletedNCT00479817Phase 2
• AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With SorafenibCompletedNCT00467025Phase 2
• MONET1-MOtesanib NSCLC Efficacy and Tolerability StudyTerminatedNCT00460317Phase 3
• Effect of Different Doses of AMG 706 on the Gallbladder in Advanced Solid TumorsCompletedNCT00448786Phase 1
• AMG 714 20060349 Multiple Dose Study in Moderate to Severe Psoriasis SubjectsCompletedNCT00443326Phase 2
• Ancillary Study to Protocol 20060104CompletedNCT00439894
• Extension From Weekly to Once Every Other Week Darbepoetin Alfa Administration in Subjects With Chronic Kidney Disease Receiving DialysisCompletedNCT00436995Phase 3
• Phase II Study to Evaluate the Efficacy of AMG 317CompletedNCT00436670Phase 2
• Phase 2 AMG 714 in Rheumatoid ArthritisCompletedNCT00433875Phase 2
• A Phase II Study to Treat Advanced Malignant GliomaCompletedNCT00427440Phase 2
• Study for Patients Who Have Benefited and Tolerated Prior Panitumumab TreatmentCompletedNCT00425204Phase 2
• Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2CompletedNCT00425035Phase 2
• A Phase II Study to Treat Subjects With Advanced Renal Cell CarcinomaCompletedNCT00422019Phase 2
• Etanercept SFP in RA PatientsCompletedNCT00413452Phase 3
• Post Transplant StudyCompletedNCT00395902
• A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Stage 2B or 3 Locally Advanced, Colon CancerCompletedNCT00393822Phase 2/3
• STAAR-1 Clinical StudyCompletedNCT00369772Phase 4
• STAAR-3 Clinical StudyCompletedNCT00369733Phase 4
• Long-Term Assessment of Safety and Physical Function With AMG 108 in RACompletedNCT00369473Phase 2
• A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLCTerminatedNCT00369070Phase 2
• STAAR-2 Clinical StudyCompletedNCT00368901Phase 4
• An Open Label Treatment Extension Study of AMG 706TerminatedNCT00360867Phase 2
• A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast CancerTerminatedNCT00356681Phase 2
• 16.0040 Ankylosing Spondylitis StudyCompletedNCT00356356Phase 3
• Veliflapon (DG-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable AnginaSuspendedNCT00353067Phase 3
• Safety Evaluation of Panitumumab and Sirolimus in Advanced Non-Small Cell Lung CancerWithdrawnNCT00352950Phase 1
• An Open-Label Study to Assess the Rate of Failure of an Enbrel® (Etanercept) SureClick™ Auto-injector in Subjects With Rheumatoid ArthritisCompletedNCT00346294Phase 4
• Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal CancerCompletedNCT00327119Phase 2
• Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast CancerCompletedNCT00322400Phase 1
• Double-blind, Randomized, Placebo-controlled Phase 3 Study of Etanercept in the Treatment of Psoriatic Arthritis and PsoriasisCompletedNCT00317499Phase 3
• A Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn's DiseaseCompletedNCT00306215Phase 2
• A Multiple Dose Study to Evaluate Subcutaneous AMG 108 in Subjects With Rheumatoid ArthritisCompletedNCT00293826Phase 2
• A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With CancerCompletedNCT00277160Phase 4
• ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast CancerCompletedNCT00261313Phase 2
• Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal TumorsCompletedNCT00254267Phase 2
• Enbrel Liquid Immunogenicity ProtocolCompletedNCT00249041Phase 3
• Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid MalignanciesCompletedNCT00239239Phase 2
• A Multi-Center, Observational Registry of Subjects With Secondary Hyperparathyroidism (HPT) and Chronic Kidney Disease (CKD)CompletedNCT00189501
• Epoetin Alfa (EPO) in Subjects With Chronic Kidney Disease (CKD)TerminatedNCT00156962Phase 3
• EPO Deep Tank in Dialysis SubjectsCompletedNCT00156949Phase 3
• Study for the Treatment of Anemia in Patients With Non-myeloid Malignancies Receiving Multicycle Chemotherapy.CompletedNCT00148421Phase 3
• A Multi-Center, Observational Safety Registry of Subjects With Idiopathic Parkinson's Disease Previously Treated With Intraputaminal Infusion of LiaterminCompletedNCT00148369
• Efficacy of Epoetin Alfa Deep Tank in Treatment of Anemia in Patients With Chronic Kidney Disease Receiving HemodialysisCompletedNCT00146224Phase 3
• Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to ChemotherapyCompletedNCT00144131Phase 2
• AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects With Nonmyeloid MalignanciesCompletedNCT00135317Phase 3
• ACHIEVE: Optimizing the Treatment of Secondary HyperparathyroidismCompletedNCT00135304Phase 4
• START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary HyperparathyroidismCompletedNCT00132431Phase 4
• Study of Enbrel in Rheumatoid Arthritis (RA) Subjects With Comorbid DisordersCompletedNCT00132418Phase 4
• A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck CancerCompletedNCT00131638Phase 3
• FIRST - Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive ChemotherapyCompletedNCT00125723Phase 4
• A Study of Cyclophosphamide/Methotrexate/5-Fluorouracil (CMF) With Pegfilgrastim in Subjects With Breast CancerCompletedNCT00124111Phase 2
• An Evaluation of Aranesp® in Subjects With Anaemic Chronic Kidney Disease (CKD)CompletedNCT00124098Phase 3
• A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid CancerCompletedNCT00121628Phase 2
• Study of Etanercept in the Treatment of Psoriasis in Adult SubjectsCompletedNCT00121615Phase 3
• Efficacy Study: Darbepoetin Alfa for the Treatment of Anemia in Patients With Chronic Kidney DiseaseCompletedNCT00121602Phase 3
• REKinDLE: Registry With Enbrel® or Kineret® in a Database Using Longitudinal EvaluationsCompletedNCT00121056
• Evaluating Kineret® (Anakinra) in Rheumatoid Arthritis (RA) Subjects Using aSelf-Reported QuestionnaireCompletedNCT00121043Phase 4
• Treatment for Patients With Gynecological Malignancies Who Suffer From Anemia Due to ChemotherapyCompletedNCT00121030Phase 2
• Treatment for Anemic Subjects With Non-Myeloid Malignancies Receiving ChemotherapyCompletedNCT00120705Phase 2
• Treatment for Patients Suffering From Anemia Due to ChemotherapyCompletedNCT00120692Phase 2
• Treatment for Patients With Non-Small Cell Lung Cancer Who Developed Anemia Due to ChemotherapyCompletedNCT00120679Phase 2
• A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin AlfaCompletedNCT00119613Phase 3
• A Study of AMG 114 Administered by Subcutaneous Injection for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies Receiving Multicycle ChemotherapyTerminatedNCT00119600Phase 1/2
• Darbepoetin Alfa Treatment of Anemia in Hemodialysis SubjectsCompletedNCT00119587Phase 3
• A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle ChemotherapyCompletedNCT00118638Phase 3
• Treatment for Elderly Patients With High Risk Breast CancerCompletedNCT00117910Phase 3
• Treatment for Subjects With Non-Hodgkin's LymphomaCompletedNCT00117897Phase 2
• A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With a Non-Myeloid MalignancyCompletedNCT00117624Phase 3
• A Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy With Pegfilgrastim or Filgrastim in Subjects With Non-Hodgkin's LymphomaCompletedNCT00117455Phase 2
• A Study of Carboplatin/Paclitaxel With Pegfilgrastim Supported by Haematopoietic Progenitor Cell Re-Infusion in Whole BloodCompletedNCT00117442Phase 2
• A Study of Repeat-Dose Subcutaneous Darbepoetin Alfa in Subjects With Congestive Heart Failure and Anemia, and a Single Dose in Healthy Age- and Sex-Matched Control SubjectsCompletedNCT00117247Phase 1/2
• Impact of Darbepoetin Alfa on Exercise Tolerance and Left Ventricular Structure in Subjects With Symptomatic Congestive Heart Failure (CHF) and AnemiaCompletedNCT00117234Not applicable
• Study to Evaluate Effectiveness of Aranesp®CompletedNCT00117130Phase 4
• A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp®CompletedNCT00117117Phase 4
• Evaluating Aranesp® in Subjects With End Stage Renal Disease onChronic HemodialysisCompletedNCT00117104Phase 4
• Anakinra (Kineret®) in Combination With Disease Modifying Anti-Rheumatic Drugs (DMARDS) in Subjects With Active Rheumatoid Arthritis (RA)CompletedNCT00117091Phase 3
• Aranesp® Monthly Preference Study - 2CompletedNCT00117078Phase 4
• Study of Transplant Related Anemia Treated With Aranesp® (STRATA)CompletedNCT00117065Phase 4
• SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary HyperparathyroidismCompletedNCT00117052Phase 3
• A Study to Evaluate the Effectiveness of Aranesp® for Cancer Patients With AnemiaCompletedNCT00117039Phase 4
• Rheumatoid Arthritis DMARD Intervention and UtilizationStudyCompletedNCT00116727
• Rheumatoid Arthritis (DMARD) Intervention and UtilizationStudyCompletedNCT00116714
• Treatment for Subjects With Chronic Kidney Disease Receiving HaemodialysisCompletedNCT00116701Phase 3
• Study of Liatermin (r-metHuGDNF) Administered by Bilateral Intraputaminal (IPu) Infusion to Subjects With Idiopathic Parkinson's DiseaseCompletedNCT00115427Phase 1
• Same Day Dosing of Pegfilgrastim in Breast Cancer Patients Undergoing Chemotherapy (TAC)CompletedNCT00115414Phase 2

← Amgen overview and focus areas